Possibility of active targeting to tumor tissues with liposomes

被引:166
作者
Maruyama, K [1 ]
Ishida, O [1 ]
Takizawa, T [1 ]
Moribe, K [1 ]
机构
[1] Teikyo Univ, Fac Pharmaceut Sci, Sagamiko, Kanagawa 1990195, Japan
关键词
active targeting; immunoliposome; polyethyleneglycol; transferrin; extravasation;
D O I
10.1016/S0169-409X(99)00042-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
lIn terms of active targeting by immunoliposomes, two anatomical compartments are considerable for targeting sites. One is located a readily accessible site in intravascular, and another is a much less accessible target site located in the extravascular. However, it was made clear that the active targeting with immunoliposomes is determined by two kinetically competing processes, such as binding to the target site and uptake by the RES. To overcome these contradictions, we have designed a new type of long-circulating immunoliposome, which was PEG-immunoliposome attached antibodies at the distal end of PEG chain, so called the pendant type immunoliposome. The pendant type immunoliposome showed much higher targetability than the ordinary immunoliposomes to both targeting sites of lung endothelial cells and solid tumor tissue. This is due to the free PEG chains (not linked to the antibody) effectively avoiding the RES uptake of liposomes, resulting in elevated the blood concentration and enhanced the target binding of immunoliposomes. The presence of free PEG does not interfere with the binding of the terminally linked antibody to the antigen. For targeting to the vascular endothelial surface in the lung, 34A antibody, which is highly specific to mouse pulmonary endothelial cells, was conjugated to make the pendant type immunoliposomes (34A-PEG-ILP). 34A-PFG-ILP showed significantly higher targeting degree than the ordinary type of immunoliposomes. For targeting to the solid tumor tissue, Fab' fragment of 21B2 antibody which is anti-human CFA and transferrin (TF) were used. Both pendant type immunoliposomes (Fab'-PFG-ILP and TF-PEG-ILP) showed the low RES uptake and the long circulation time, and resulted in enhanced accumulation of the liposomes in the solid tumor. TF-PEG-ILP was internalized into tumor cells with receptor mediated endocytosis, after extravasation into tumor tissue. The pendant type immunoliposome can escape from the gaps between adjacent endothelial cells and openings at the vessel termini during tumor angiogenesis by passive convective transport much rather than ligand directed targeting. Active targeting to tumor tissue with the pendant type immunoliposome is particularly important for many highly toxic anticancer drugs for cancer chemotherapy. An ultimate goal of pendant type immunoliposome is the incorporation of a fusogenic molecule that would induce fusion of Liposome following their binding to the target cells or their internalization by endocytosis. Such liposomal formulations should be useful for endocytotic internalization of plasmid DNA and other bioactive materials. (C) 1999 Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:89 / 102
页数:14
相关论文
共 38 条
[1]   LIPOSOMES CONTAINING SYNTHETIC LIPID DERIVATIVES OF POLY(ETHYLENE GLYCOL) SHOW PROLONGED CIRCULATION HALF-LIVES INVIVO [J].
ALLEN, TM ;
HANSEN, C ;
MARTIN, F ;
REDEMANN, C ;
YAUYOUNG, A .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1066 (01) :29-36
[2]   LARGE UNILAMELLAR LIPOSOMES WITH LOW UPTAKE INTO THE RETICULOENDOTHELIAL SYSTEM [J].
ALLEN, TM ;
CHONN, A .
FEBS LETTERS, 1987, 223 (01) :42-46
[3]   IMMUNE CLEARANCE OF LIPOSOMES INHIBITED BY AN ANTI-FC RECEPTOR ANTIBODY INVIVO [J].
ARAGNOL, D ;
LESERMAN, LD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (08) :2699-2703
[4]  
CUMMINGS J, 1993, TOPICS PHARM, V3, P27
[5]   UPTAKE AND PROCESSING OF IMMUNOGLOBULIN-COATED LIPOSOMES BY SUBPOPULATIONS OF RAT-LIVER MACROPHAGES [J].
DERKSEN, JTP ;
MORSELT, HWM ;
SCHERPHOF, GL .
BIOCHIMICA ET BIOPHYSICA ACTA, 1988, 971 (02) :127-136
[6]  
DVORAK HF, 1988, AM J PATHOL, V133, P95
[7]  
EHRLICH PA, 1956, IMMUNOLOGY CANC RES
[8]  
GATTER K, 1987, J CLIN PATHOL, V36, P539
[9]   DRUG TARGETING IN CANCER-CHEMOTHERAPY - A CLINICAL PERSPECTIVE [J].
GUPTA, PK .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1990, 79 (11) :949-962
[10]  
HUANG SK, 1992, CANCER RES, V52, P5135